ProVise Management Group LLC Grows Holdings in Zoetis Inc (ZTS)
ProVise Management Group LLC boosted its holdings in Zoetis Inc (NYSE:ZTS) by 13.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 9,283 shares of the company’s stock after purchasing an additional 1,104 shares during the quarter. ProVise Management Group LLC’s holdings in Zoetis were worth $668,000 at the end of the most recent quarter.
Other institutional investors have also added to or reduced their stakes in the company. Harel Insurance Investments & Financial Services Ltd. acquired a new position in Zoetis in the fourth quarter worth $108,000. Steward Partners Investment Advisory LLC acquired a new position in Zoetis in the third quarter worth $114,000. Mitsubishi UFJ Securities Holdings Co. Ltd. boosted its holdings in Zoetis by 251.9% in the third quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 1,900 shares of the company’s stock worth $121,000 after purchasing an additional 1,360 shares during the period. Shine Investment Advisory Services Inc. boosted its holdings in shares of Zoetis by 86.5% during the third quarter. Shine Investment Advisory Services Inc. now owns 2,242 shares of the company’s stock valued at $143,000 after acquiring an additional 1,040 shares during the period. Finally, McKinley Carter Wealth Services Inc. acquired a new position in shares of Zoetis during the third quarter valued at $201,000. 93.72% of the stock is owned by hedge funds and other institutional investors.
Shares of Zoetis Inc (NYSE:ZTS) opened at $73.24 on Wednesday. Zoetis Inc has a one year low of $52.00 and a one year high of $80.13. The company has a current ratio of 2.80, a quick ratio of 1.95 and a debt-to-equity ratio of 2.45. The firm has a market cap of $35,690.00, a PE ratio of 38.55, a P/E/G ratio of 1.60 and a beta of 1.07.
Several equities analysts have recently issued reports on the stock. Piper Jaffray Companies reissued a “buy” rating and set a $86.00 price target on shares of Zoetis in a report on Thursday, January 18th. BMO Capital Markets set a $78.00 price target on shares of Zoetis and gave the company a “hold” rating in a report on Monday, January 22nd. Jefferies Group reissued a “buy” rating and set a $89.00 price target on shares of Zoetis in a report on Tuesday, January 16th. Zacks Investment Research downgraded shares of Zoetis from a “hold” rating to a “sell” rating and set a $83.00 price target for the company. in a report on Saturday, January 13th. Finally, Cantor Fitzgerald set a $85.00 price target on shares of Zoetis and gave the company a “buy” rating in a report on Thursday, January 11th. Two research analysts have rated the stock with a sell rating, four have issued a hold rating and fourteen have given a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $73.72.
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc (NYSE:ZTS).
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.